Restless Legs Syndrome (RLS) Background information for medical media outside the US only This selection gives an overview on background material for Restless Legs Syndrome (RLS) available on the Boehringer Ingelheim corporate website.

Press Releases

• 26 August 2008Pramipexole clinical trial programme in Restless Legs Syndrome (RLS) reveals new significant results
• 17 April 2008New data confirm pramipexole (Mirapexin®/Sifrol®) can significantly reduce sleep disturbance for people with Restless Legs Syndrome (RLS)
• 08 June 2007Efficacy of Boehringer Ingelheim's pramipexole (Mirapexin®/Sifrol®) also demonstrated in patients with daytime RLS symptoms
• 10 November 2006FDA approves Boehringer Ingelheim's pramipexole for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
• press release archive

Documents

• Restless Legs Syndrome Information Sheet - PDF (149 KB)
• Pramipexole Information Sheet - PDF (129 KB)